Bli medlem
Bli medlem

Du är här


BioStock: Update from Arcede Pharma CEO

Arcede Pharma develops RCD405, a dual-action drug candidate for the treatment of COPD and severe asthma. The company is underway with the final part of the preclinical development, where it is waiting for final results from the toxicology program. Recently, the team was expanded with two scientific advisors, both leading experts in the respiratory field. In an interview in connection with the BioStock Investor Meeting, Arcede Pharma's CEO Mia Lundblad gave an update.

See the full interview at (

This is a press release from BioStock - Connecting Innovation & Capital.

Författare Cision